Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
Study of RMC-6291 in Patients with Advanced Solid Tumors
Sponsor: Revolution Medicines, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU3396
U.S. Govt. ID: NCT05462717
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test a new drug called RMC-6291, to evaluate its safety at different doses, and to find out how the body processes it. RMC-6291 is a new experimental drug, which means that it is not approved by the US Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6291 will be tested in humans. Cancers include: bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, ovarian cancer, head and neck/oral cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a life expectancy of more than 3 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator